White House Clarifies Press Release Claiming Trump Ended COVID-19 Pandemic; Administration Agrees To Purchase At Least $375M Of Lilly’s Experimental Antibody Drug
The Hill: White House seeks to clarify press release claiming Trump ended the COVID-19 pandemic
“A press release claiming that President Trump ended the coronavirus pandemic was ‘poorly worded’ and Trump does not believe the pandemic is over, a White House spokesperson said Wednesday. ‘The intent was to say that it is our goal to end the virus,’ White House strategic communications director Alyssa Farah said during a Fox News interview. ‘Cases are still rising and we need the American public to remain vigilant. This is the top priority of the president, defeating this virus and rebuilding our economy,’ Farah said…” (Weixel, 10/28).
The Hill: Trump administration agrees to purchase $375 million of Lilly coronavirus antibody drug
“The Trump administration will pay Eli Lilly $375 million to supply 300,000 doses of its experimental antibody drug to treat COVID-19, the Department of Health and Human Services said Wednesday. … The initial agreement is for delivery over the course of two months following authorization, with the option to purchase up to 650,000 additional doses through the end of June 2021 for up to an additional $812.5 million. … The announcement of the agreement comes a day after Eli Lilly said the drug had no clinical benefit for helping hospitalized patients. The company said it is confident the drug is helpful to those earlier in the course of a COVID-19 infection…” (Weixel, 10/28).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.